{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:31:24Z","timestamp":1792985484337,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003064","name":"Kidney Cancer Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012287","name":"Andrew Sabin Family Foundation","doi-asserted-by":"publisher","award":["KC200096P1"],"award-info":[{"award-number":["KC200096P1"]}],"id":[{"id":"10.13039\/100012287","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.urolonc.2024.12.267","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T23:53:07Z","timestamp":1736380387000},"page":"188.e9-188.e17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Concomitant antihistamine administration is associated with improved survival outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with atezolizumab. Analysis of individual participant data from IMvigor210 and IMvigor211"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7872-2650","authenticated-orcid":false,"given":"Giuseppe","family":"Fallara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Belladelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Robesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Malavaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00f4me","family":"Tholomier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharada","family":"Mokkapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin P.","family":"Dinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlos","family":"Msaouel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.12.267_bib0001","unstructured":"Surveillance, epidemiology, and End Results Program. Cancer stat facts: bbladder cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html. (accessed July 12, 2022)."},{"issue":"21","key":"10.1016\/j.urolonc.2024.12.267_bib0002","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2024.12.267_bib0003","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","article-title":"A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study","volume":"10","author":"Loehrer","year":"1992","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"27","key":"10.1016\/j.urolonc.2024.12.267_bib0004","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","article-title":"Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract","volume":"27","author":"Bellmunt","year":"2009","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.12.267_bib0005","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1200\/JCO.2011.37.7002","article-title":"Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer","volume":"30","author":"Choueiri","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.urolonc.2024.12.267_bib0006","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/annonc\/mdu223","article-title":"Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Bellmunt","year":"2014","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"10122","key":"10.1016\/j.urolonc.2024.12.267_bib0007","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet Lond Engl"},{"issue":"10064","key":"10.1016\/j.urolonc.2024.12.267_bib0008","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet Lond Engl"},{"issue":"10","key":"10.1016\/j.urolonc.2024.12.267_bib0009","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1158\/1078-0432.CCR-21-3089","article-title":"Putative biomarkers of clinical benefit with Pembrolizumab in advanced urothelial cancer: results from the KEYNOTE-045 and KEYNOTE-052 landmark trials","volume":"28","author":"Bellmunt","year":"2022","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"3","key":"10.1016\/j.urolonc.2024.12.267_bib0010","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.urolonc.2024.12.267_bib0011","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.urolonc.2024.12.267_bib0012","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.267_bib0013","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 updated European Association of Urology Guidelines on metastatic urothelial carcinoma","volume":"81","author":"Cathomas","year":"2022","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.12.267_bib0014","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.urolonc.2024.12.267_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102360","article-title":"Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: a systematic review and meta-analysis","volume":"104","author":"Martini","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"10.1016\/j.urolonc.2024.12.267_bib0016","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1080\/0284186X.2020.1769185","article-title":"Desloratadine and loratadine stand out among common H1-antihistamines for association with improved breast cancer survival","volume":"59","author":"Fritz","year":"2020","journal-title":"Acta Oncol Stockh Swed"},{"issue":"8","key":"10.1016\/j.urolonc.2024.12.267_bib0017","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/all.14273","article-title":"Desloratadine and loratadine use associated with improved melanoma survival","volume":"75","author":"Fritz","year":"2020","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.urolonc.2024.12.267_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101029","article-title":"Improved survival in several cancers with use of H1-antihistamines desloratadine and loratadine","volume":"14","author":"Fritz","year":"2021","journal-title":"Transl Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.267_bib0019","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ccell.2021.11.002","article-title":"The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"issue":"10031","key":"10.1016\/j.urolonc.2024.12.267_bib0020","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"10.1016\/j.urolonc.2024.12.267_bib0021","doi-asserted-by":"crossref","first-page":"271.e1","DOI":"10.1016\/j.clgc.2020.08.003","article-title":"Causal diagram techniques for urologic oncology research","volume":"19","author":"Shapiro","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.267_bib0022","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"30","key":"10.1016\/j.urolonc.2024.12.267_bib0023","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1200\/JCO.19.00318","article-title":"Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody","volume":"37","author":"Maher","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.12.267_bib0024","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/bju.16121","article-title":"The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trials","volume":"133","author":"Robesti","year":"2024","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.267_bib0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2024.12.267_bib0026","unstructured":"Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 10th ed. Philadelphia: Elsevier; 2021. ISBN: 9780323757492."},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.267_bib0027","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/j.cllc.2020.07.016","article-title":"The impact of beta blockers on survival outcomes in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors","volume":"22","author":"Oh","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"10.1016\/j.urolonc.2024.12.267_bib0028","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1080\/10428194.2017.1397662","article-title":"Drugging DNA repair to target T-ALL cells","volume":"59","author":"Dasgupta","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.urolonc.2024.12.267_bib0029","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1523-1747.2000.00054.x","article-title":"Histidine decarboxylase expression in human melanoma","volume":"115","author":"Haak-Frendscho","year":"2000","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.12.267_bib0030","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/BF00398182","article-title":"Blood histamine and solid malignant tumors","volume":"114","author":"Moriarty","year":"1988","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.12.267_bib0031","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.breast.2004.06.012","article-title":"Concentration of histamine in serum and tissues of the primary ductal breast cancers in women","volume":"14","author":"Sieja","year":"2005","journal-title":"Breast Edinb Scotl"},{"issue":"3","key":"10.1016\/j.urolonc.2024.12.267_bib0032","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/bph.14535","article-title":"Histamine receptors and cancer pharmacology: an update","volume":"177","author":"Massari","year":"2020","journal-title":"Br J Pharmacol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924010470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924010470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:31:56Z","timestamp":1762363916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924010470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1078143924010470"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.12.267","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concomitant antihistamine administration is associated with improved survival outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with atezolizumab. Analysis of individual participant data from IMvigor210 and IMvigor211","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.12.267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}